Effectiveness of 32 versus 20 weeks of prednisolone in leprosy patients with recent nerve function impairment: A randomized controlled trial.

• 主要な著者: Inge Wagenaar (著者), Erik Post (著者), Wim Brandsma (著者), Bob Bowers (著者), Khorshed Alam (著者), Vanaja Shetty (著者), Vivek Pai (著者), Sajid Husain (著者), Cita Rosita Sigit Prakoeswa (著者), Linda Astari (著者), Deanna Hagge (著者), Mahesh Shah (著者), Kapil Neupane (著者), Krishna Bahadur Tamang (著者), TENLEP study group (著者), Peter Nicholls (著者), Jan Hendrik Richardus (著者)
• フォーマット: 図書
• 出版事項: Public Library of Science (PLoS), 2017-10-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

While prednisolone is commonly used to treat recent nerve function impairment (NFI) in leprosy patients, the optimal treatment duration has not yet been established. In this "Treatment of Early Neuropathy in Leprosy" (TENLEP) trial, we evaluated whether a 32-week prednisolone course is mor...